{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:05Z","timestamp":1786980185662,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T00:00:00Z","timestamp":1256947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00431-009-1090-1","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T16:08:56Z","timestamp":1256918936000},"page":"689-693","source":"Crossref","is-referenced-by-count":33,"title":["Clinical practice"],"prefix":"10.1007","volume":"169","author":[{"given":"Hanaa","family":"El-Karaksy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohmmad","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokaya","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Raziky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"El-Koofy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"El-Hawary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Al-Dirbashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,31]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200666060-00002","volume":"66","author":"PJ McKiernan","year":"2006","unstructured":"McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66:743\u2013750","journal-title":"Drugs"},{"key":"1090_CR2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/hmg\/2.7.941","volume":"2","author":"Y Labelle","year":"1993","unstructured":"Labelle Y, Phaneuf D, Leclerc B et al (1993) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 2:941\u2013946","journal-title":"Hum Mol Genet"},{"key":"1090_CR3","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1073\/pnas.74.10.4641","volume":"74","author":"B Lindblad","year":"1977","unstructured":"Lindblad B, Lindstedt S, Steen G (1977) On the enzymatic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74:4641\u20134645","journal-title":"Proc Natl Acad Sci USA"},{"key":"1090_CR4","first-page":"1777","volume-title":"The metabolic and molecular bases of inherited disease","author":"GA Mitchell","year":"2001","unstructured":"Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosnemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw Hill Co, New York, pp 1777\u20131806","edition":"8"},{"key":"1090_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02820214","volume":"73","author":"S Bijarnia","year":"2006","unstructured":"Bijarnia S, Puri RD, Ruel J et al (2006) Tyrosinemia type 1\u2014Diagnostic issues and prenatal diagnosis. Indian J Pediatr 73:163\u2013165","journal-title":"Indian J Pediatr"},{"key":"1090_CR6","first-page":"27","volume":"184","author":"EA Kvittingen","year":"1986","unstructured":"Kvittingen EA (1986) Hereditary tyrosinemia type 1\u2014an overview. Scand J Clin Invest Suppl 184:27\u201334","journal-title":"Scand J Clin Invest Suppl"},{"key":"1090_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1005410820201","volume":"21","author":"E Holme","year":"1998","unstructured":"Holme E, Lindstedt S (1998) Tyrosinemia type 1 and NTBC. J Inherit Metabol Dis 21:507\u2013517","journal-title":"J Inherit Metabol Dis"},{"key":"1090_CR8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","volume":"340","author":"S Lindstedt","year":"1992","unstructured":"Lindstedt S, Holme E, Lock EA et al (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813\u2013817","journal-title":"Lancet"},{"key":"1090_CR9","first-page":"338","volume":"47","author":"K Paradis","year":"1990","unstructured":"Paradis K, Weber A, Seidman EG et al (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47:338\u2013342","journal-title":"Am J Hum Genet"},{"key":"1090_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/14656566.9.1.129","volume":"9","author":"S Santra","year":"2008","unstructured":"Santra S, Baumann U (2008) Experience of nistinone for the pharmacological treatment of hereditary tyrosinemia type 1. Epert Opin Pharmacother 9:129\u2013136","journal-title":"Epert Opin Pharmacother"},{"key":"1090_CR11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1179\/027249304225019000","volume":"24","author":"SN Joshi","year":"2004","unstructured":"Joshi SN, Venugopalan P (2004) Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation. Ann Trop Paediatr 24:259\u2013265","journal-title":"Ann Trop Paediatr"},{"key":"1090_CR12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1089-3261(05)70142-2","volume":"4","author":"E Holme","year":"2000","unstructured":"Holme E, Lindsedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805\u2013814","journal-title":"Clin Liver Dis"},{"key":"1090_CR13","unstructured":"Jenkins J (2002) Orphadin. FDA.gov. Available via http:\/\/www.fda.gov\/cder\/foi\/label\/2002\/21232lbl.pdf . Accessed 10 July 2008"},{"key":"1090_CR14","unstructured":"Roth KS (2007) Tyrosinemia (emedicine website). Available via http:\/\/www.emedicine.com\/ped\/TOPIC2339.HTM . Accessed 10 July 2008"},{"key":"1090_CR15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jchromb.2005.12.010","volume":"831","author":"OY Al-Dirbashi","year":"2006","unstructured":"Al-Dirbashi OY, Rashed MS, Brink HJ et al (2006) Determination of succinyl acetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 831:274\u2013280","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-009-1090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-009-1090-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-009-1090-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:22:03Z","timestamp":1559067723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-009-1090-1"}},"subtitle":["NTBC therapy for tyrosinemia type 1: how much is enough?"],"short-title":[],"issued":{"date-parts":[[2009,10,31]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s00431-009-1090-1","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,31]]}}}